What are common treatments for myasthenia gravis?

Myasthenia gravis is an autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The pathophysiology involves the immune system attacking acetylcholine receptors at the neuromuscular junction, leading to impaired muscle contraction.

Anticholinesterase drugs, such as pyridostigmine, are commonly used to manage myasthenia gravis by inhibiting the enzyme that breaks down acetylcholine, thereby increasing its availability and enhancing communication between nerves and muscles. This helps reduce muscle weakness.

Additionally, plasmapheresis is an effective treatment for myasthenia gravis, especially during myasthenic crises or exacerbations. This procedure removes antibodies from the bloodstream that are disrupting muscle function. Plasmapheresis can provide rapid symptomatic relief and is often used in acute scenarios or when patients do not respond adequately to medication.

Together, anticholinesterase drugs and plasmapheresis form a critical component of the treatment regimen for this condition. The other options listed involve medications that either do not have a role in treating myasthenia gravis or focus on other conditions entirely, thus making them unsuitable for managing this specific disorder.